Recommended Topical Treatment Plan for Eczema
For eczema treatment, start with liberal daily moisturizers combined with topical corticosteroids as the mainstay of therapy, using the least potent preparation needed to control disease and applying twice daily to active lesions. 1, 2
Foundation: Moisturization and Skin Care
Moisturizers are essential for all eczema patients and should be applied liberally, ideally after bathing when the skin is still hydrated 2. The evidence strongly supports their use for reducing flares and decreasing the need for topical corticosteroids 3. While no specific moisturizer formulation can be universally recommended, emollients containing glycyrrhetinic acid, urea, or glycerol show superior efficacy compared to vehicle controls 3.
Key skin care principles:
- Avoid soaps and detergents - use soap-free cleansers or dispersible creams as soap substitutes 1
- Bathing is beneficial for cleansing and hydrating skin 1, 2
- Apply moisturizers immediately after bathing to lock in hydration 1
- Keep nails short to minimize trauma from scratching 1
- Avoid wool clothing directly on skin; cotton is preferred 1
First-Line Anti-Inflammatory Treatment: Topical Corticosteroids
Topical corticosteroids remain the cornerstone of eczema treatment with strong evidence for efficacy and safety when used appropriately 1, 2, 4. The fundamental principle: use the least potent preparation required to achieve control, applied no more than twice daily 1.
Corticosteroid selection strategy:
- Mild-to-moderate eczema: Start with low-to-medium potency corticosteroids (e.g., hydrocortisone, prednicarbate 0.02%) 1, 5
- Severe or lichenified areas: May require potent preparations for limited periods 1
- Face and intertriginous areas: Use only low-potency preparations due to increased absorption 1
Maintenance therapy:
Once control is achieved, use medium-potency topical corticosteroids intermittently (twice weekly) on previously affected areas to prevent flares and reduce relapse rates 2. This proactive approach is strongly recommended based on high-quality evidence 2.
Critical safety points:
- Very potent and potent corticosteroids should be used cautiously for limited periods only 1
- The main risk is pituitary-adrenal axis suppression, particularly in children 1
- Local side effects (skin atrophy, striae) are potency-dependent and occur primarily with prolonged use of potent preparations 6, 4
- Patient education is essential - many patients undertreat due to steroid phobia 1
Alternative Anti-Inflammatory Options
Topical Calcineurin Inhibitors (TCIs)
For adults with moderate-to-severe eczema, tacrolimus 0.03% or 0.1% ointment is strongly recommended 2. For mild-to-moderate disease, pimecrolimus 1% cream is strongly recommended 2. These are particularly valuable when:
- Corticosteroid side effects are a concern (face, eyelids, intertriginous areas)
- Long-term maintenance therapy is needed
- Patients are intolerant of or unresponsive to corticosteroids 6
TCIs can be used for short-term or intermittent long-term treatment in patients ≥2 years old 6. The risk-benefit ratio is similar to conventional therapies, and concerns about malignancy risk from the black box warning are not supported by current data - actual lymphoma rates are lower than predicted in the general population 6.
Newer Topical Agents (Strong Recommendations)
For adults with mild-to-moderate eczema, the following have strong evidence support:
- Crisaborole ointment (PDE-4 inhibitor) 2
- Ruxolitinib cream (JAK inhibitor) 2
- Tapinarof cream 7
- Roflumilast cream 7
What NOT to Use
Conditional recommendations AGAINST:
- Topical antimicrobials - not routinely indicated unless clear infection is present 2, 8
- Topical antihistamines - limited value 2
- Topical antiseptics - except bleach baths may be considered for moderate-to-severe eczema with clinical signs of secondary bacterial infection 2
- Non-sedating oral antihistamines - have little to no value in eczema 1
When Topical Therapy Fails
If eczema remains uncontrolled despite optimized topical therapy:
- Reassess the diagnosis - consider contact dermatitis, cutaneous lymphoma, or other mimics 9
- Evaluate for secondary infection - bacterial (crusting, weeping) or viral (grouped erosions suggesting herpes simplex) 1
- Consider phototherapy or systemic agents - the 2024 AAD guidelines make strong recommendations for dupilumab, tralokinumab, abrocitinib, baricitinib, and upadacitinib for moderate-to-severe disease 9
Systemic therapy hierarchy:
Dupilumab is the preferred first-line systemic agent - all guideline workgroup members favored it, with excellent safety track record and efficacy 9. Alternative biologics (tralokinumab, lebrikizumab) and JAK inhibitors are also strongly recommended 9, 7.
Systemic corticosteroids receive a conditional recommendation AGAINST use - they should be restricted to exceptional, short-term rescue situations only due to significant toxicities including rebound flares, adrenal suppression, and metabolic complications 9, 4.
Special Considerations
Wet Wrap Therapy
Conditionally recommended for moderate-to-severe flares - involves applying topical medications followed by wet dressings, though this adds complexity to treatment regimens 2, 10.
Infection Management
- Bacterial infection (usually S. aureus): Treat with flucloxacillin or erythromycin if penicillin-allergic 1
- Eczema herpeticum: Requires oral acyclovir started early; use IV if patient is febrile or ill 1
- Bleach baths may reduce bacterial colonization in moderate-to-severe cases 2, 10
Application Technique
- Apply treatments no more than twice daily 1
- Some newer preparations require only once-daily application 1
- Demonstrate proper application technique - patient education significantly improves outcomes 1
This algorithmic approach prioritizes evidence-based treatments while avoiding therapies with limited benefit, ensuring optimal disease control while minimizing risks.